<DOC>
	<DOC>NCT01598571</DOC>
	<brief_summary>Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer dose.</brief_summary>
	<brief_title>Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose</brief_title>
	<detailed_description>A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers.</detailed_description>
	<criteria>Healthy male volunteers aged 18 to 55 years (inclusive), with a weight of at least 50 kg and a body mass index (BMI) between 18 and 30 kg/m2 (inclusive) Male volunteers willing to use barrier contraception ie, condoms with spermicide, from the first day of the investigational product administration until 3 months after the last administration of the investigational product History of any clinically significant disease or disorder History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of drug Volunteers who smoke more than 5 cigarettes or the equivalent in tobacco per day Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results as judged by the Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy male volunteers</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>fostamatinib</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>R406 plasma AUC and Cmax</keyword>
	<keyword>R406 plasma AUC0-t</keyword>
	<keyword>t1/2Î»z</keyword>
	<keyword>tmax</keyword>
</DOC>